Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

Contributed by: GlobeNewswire

Tags

nuclear medicine

More Like This

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

PR Newswire associated0

Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

PR Newswire associated0

Global supply chain for Lu-177 based cancer treatments strengthened by Kinectrics' start of Yb-176 production, reducing reliance on Russia

PR Newswire associated0

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera, which aims to accelerate global actinium - 225 production

PR Newswire associated0

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform